Michael P. Manns

from Wikipedia, the free encyclopedia

Michael Peter Manns (born November 16, 1951 in Koblenz ) is a German internist and university professor . In 2011 he was "by far the most cited liver, stomach and intestinal researcher in Europe".

Life

Michael P. Manns studied medicine at the University of Vienna and Johannes Gutenberg University Mainz from 1970 to 1976 . In 1976 he received his doctorate. In 1986 the University of Mainz appointed him C2 professor for internal medicine and since 1991 Manns has been director and C4 professor of the Clinic for Gastroenterology , Hepatology and Endocrinology at the Medical University of Hanover .

He was significantly involved in clinical studies for new standard therapies for chronic hepatitis and established a competence center for hepatitis (Hep-net) at the MHH, which is initially funded by the Federal Ministry of Education and Research (BMBF) from 2002 to 2010 and since 2007 by the German Liver Foundation . In 2001 he led a clinical study which showed the good effectiveness of peginterferon α together with ribavirin against hepatitis C (with the dosage adjusted to the patient's weight), until recently the standard therapy (as such, replaced by the CAR-T cell therapy). In 2012, he led a clinical study at his center that showed the effectiveness of a combination treatment with peginterferon alpha and adefovir dipivoxil (both drugs have already been used against hepatitis B and C) in the often severe chronic hepatitis D infections.

At the MHH he also developed a program for liver cell transplantation for acute liver failure in adults, which was also expanded there in 2007 to include newborns with congenital metabolic disorders. Living liver cells from donor organs (not suitable for transplantation) are injected into the blood supply to the liver and at the same time immunosuppressants are given to prevent rejection reactions. This is to bridge the time until a liver transplant. They worked together with the Cytonet company in Weinheim, which previously mainly supplied blood stem cells and bone marrow preparations for leukemia therapy.

On January 1, 2019, he took over the office of President of the Hannover Medical School.

Awards and memberships (selection)

  • 1985: Boehringer Ingelheim Prize from the University of Mainz
  • 1990: Clinical Research Award, Göttingen
  • 1991: Clemens van Pirquet Award, University of California Davis, USA
  • 1995: International Hans Popper Prize, Basel , Switzerland
  • 2002: Robert Pfleger Research Award , Bamberg
  • 2002: Member of the Leopoldina
  • 2003: Max Siurala Award, Finnish Society of Gastroenterology, Turku, Finland
  • 2003: full member of the Academy of Sciences in Göttingen
  • 2005: Honorary member of the Argentine Hepatology Society
  • 2006: Honorary member of the Hungarian Gastroenterological Society

literature

Individual evidence

  1. ↑ Innovation report Accessed on September 14, 2011
  2. ^ Informationsdienst Wissenschaft Retrieved September 14, 2011
  3. ^ MH Hannover Retrieved September 14, 2011
  4. ^ The Lancet , Volume 358, 2001, p. 9286
  5. ↑ New therapy against hepatitis Delta - a combination of two active ingredients cures every fourth patient , From Research, September 13, 2011, Federal Ministry of Education and Research, accessed on September 10, 2018.
  6. ↑ Cytonet GmbH: Saving lives through cell therapy instead of liver transplantation Biopro Baden-Württemberg GmbH, February 13, 2017.
  7. ↑ Professor Manns is the new MHH President. December 28, 2018, accessed January 2, 2019 .
  8. ^ Members of the Academy of Sciences in Göttingen: Michael Manns. Academy of Sciences in Göttingen, accessed on August 14, 2016 .
personal data
SURNAME Manns, Michael P.
ALTERNATIVE NAMES Manns, Michael Peter (full name)
BRIEF DESCRIPTION German internist and university professor
DATE OF BIRTH November 16, 1951
PLACE OF BIRTH Koblenz